术前免疫炎症指标及AFP对HCC肝切除术后 预后价值的研究现状
Research Status of Preoperative Immune-Inflammatory Markers and Alpha-Fetoprotein in Predicting Prognosis after Hepatectomy for Hepatocellular Carcinoma
摘要: 肝细胞癌(HCC)是全球癌症相关死亡的主要病因之一，早期诊断与精准预后评估对改善患者生存至关重要。近年来，术前免疫炎症指标与甲胎蛋白(AFP)在HCC患者预后评估中的价值日益受到关注。这些生物标志物不仅能反映机体全身性炎症状态，亦与肿瘤生物学行为及预后密切相关。现有研究表明，术前免疫炎症指标如中性粒细胞–淋巴细胞比值(NLR)、血小板–淋巴细胞比值(PLR)、全身免疫炎症指数(SII)等，与HCC患者术后生存率及复发风险显著相关。同时，AFP作为经典的肝癌血清标志物，其水平变化亦被证实与患者预后具有显著关联。然而，术前免疫炎症指标与AFP联合应用于术后预后预测的具体机制尚待进一步阐明。本文综述术前免疫炎症指标及AFP在HCC肝切除术后预后评估中的最新研究进展，探讨其临床转化潜力，以期为HCC术后个体化治疗策略提供依据。
Abstract: Hepatocellular carcinoma (HCC) represents one of the leading causes of cancer-related mortality worldwide. Early diagnosis and precise prognostic evaluation are crucial for improving patient survival. In recent years, the prognostic value of preoperative immune-inflammatory markers and alpha-fetoprotein (AFP) in HCC patients has garnered increasing attention. These biomarkers not only reflect the systemic inflammatory status of the host but are also closely associated with tumor biology and prognosis. Existing studies indicate that preoperative immune-inflammatory markers, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), are significantly correlated with postoperative survival rates and recurrence risk in HCC patients. Concurrently, AFP, a classic serum tumor marker for liver cancer, has also been confirmed to have a significant association with patient prognosis. However, the specific mechanisms underlying the combined application of preoperative immune-inflammatory markers and AFP for postoperative prognosis prediction require further elucidation. This article reviews the latest research progress on preoperative immune-inflammatory markers and AFP in prognostic assessment following hepatectomy for HCC, explores their potential for clinical translation, and aims to provide a basis for individualized postoperative treatment strategies for HCC.
文章引用：邹建, 牛超, 白亦焘, 王宁, 唐继红. 术前免疫炎症指标及AFP对HCC肝切除术后 预后价值的研究现状[J]. 临床医学进展, 2026, 16(3): 2692-2700. https://doi.org/10.12677/acm.2026.1631069

参考文献

[1] Petrick, J.L. and McGlynn, K.A. (2019) The Changing Epidemiology of Primary Liver Cancer. Current Epidemiology Reports, 6, 104-111. [Google Scholar] [CrossRef] [PubMed]
[2] Galle, P.R., Forner, A., Llovet, J.M., Mazzaferro, V., Piscaglia, F., Raoul, J., et al. (2018) EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69, 182-236. [Google Scholar] [CrossRef] [PubMed]
[3] Yip, T.C. and Wong, G.L. (2024) Transforming the Landscape of Liver Cancer Detection and Care. Nature Reviews Gastroenterology & Hepatology, 22, 86-87. [Google Scholar] [CrossRef] [PubMed]
[4] Xiang, Z., Deng, J., Liang, H., Jiang, M., Liang, Y., Liu, Z., et al. (2025) Artificial Intelligence for the Prediction of Posthepatectomy Recurrence in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Annals of Medicine, 57, Article ID: 2568118. [Google Scholar] [CrossRef] 
[5] Grivennikov, S.I., Greten, F.R. and Karin, M. (2010) Immunity, Inflammation, and Cancer. Cell, 140, 883-899. [Google Scholar] [CrossRef] [PubMed]
[6] Wang, M., Qian, G., Xiao, H., Liu, X., Sun, L., Chen, Z., et al. (2024) Prognostic Significance of Postoperative Serological Incomplete Conversion of AFP and PIVKA-II after Hepatic Resection for Hepatocellular Carcinoma: A Multicenter Analysis of 1755 Patients. The Oncologist, 29, e1723-e1733. [Google Scholar] [CrossRef] [PubMed]
[7] Chen, R., Yen, C., Lin, Y., Wang, J., Tasi, T., Huang, Y., et al. (2021) CPAP Enhances and Maintains Chronic Inflammation in Hepatocytes to Promote Hepatocarcinogenesis. Cell Death & Disease, 12, Article No. 983. [Google Scholar] [CrossRef] [PubMed]
[8] Tahmasebi Birgani, M. and Carloni, V. (2017) Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy. International Journal of Molecular Sciences, 18, Article 405. [Google Scholar] [CrossRef] [PubMed]
[9] 杜义江, 肖长义. 微环境与肝癌发病机制的研究进展[J]. 基础医学与临床, 2015, 35(2): 248-252.
[10] Santhakumar, C., Gane, E.J., Liu, K. and McCaughan, G.W. (2020) Current Perspectives on the Tumor Microenvironment in Hepatocellular Carcinoma. Hepatology International, 14, 947-957. [Google Scholar] [CrossRef] [PubMed]
[11] Chen, W., Tan, M., Zhang, H., Gao, T., Ren, J., Cheng, S., et al. (2024) Signaling Molecules in the Microenvironment of Hepatocellular Carcinoma. Functional & Integrative Genomics, 24, Article No. 146. [Google Scholar] [CrossRef] [PubMed]
[12] Galasso, L., Cerrito, L., Maccauro, V., Termite, F., Ainora, M.E., Gasbarrini, A., et al. (2024) Hepatocellular Carcinoma and the Multifaceted Relationship with Its Microenvironment: Attacking the Hepatocellular Carcinoma Defensive Fortress. Cancers, 16, Article 1837. [Google Scholar] [CrossRef] [PubMed]
[13] Xie, D., Liu, Y., Xu, F., Dang, Z., Li, M., Zhang, Q., et al. (2025) Immune Microenvironment and Immunotherapy in Hepatocellular Carcinoma: Mechanisms and Advances. Frontiers in Immunology, 16, Article 1581098. [Google Scholar] [CrossRef] [PubMed]
[14] Zarlashat, Y., Ghaffar, A., Guerra, F. and Picca, A. (2025) Immunological Landscape and Molecular Therapeutic Targets of the Tumor Microenvironment in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 26, Article 7836. [Google Scholar] [CrossRef] 
[15] Chen, Y., Zhou, Y., Yan, Z., Tong, P., Xia, Q. and He, K. (2023) Effect of Infiltrating Immune Cells in Tumor Microenvironment on Metastasis of Hepatocellular Carcinoma. Cellular Oncology, 46, 1595-1604. [Google Scholar] [CrossRef] [PubMed]
[16] Zhang, J., Gu, C., Song, Q., Zhu, M., Xu, Y., Xiao, M., et al. (2020) Identifying Cancer-Associated Fibroblasts as Emerging Targets for Hepatocellular Carcinoma. Cell & Bioscience, 10, Article No. 127. [Google Scholar] [CrossRef] [PubMed]
[17] Minini, M. and Fouassier, L. (2023) Cancer-Associated Fibroblasts and Extracellular Matrix: Therapeutical Strategies for Modulating the Cholangiocarcinoma Microenvironment. Current Oncology, 30, 4185-4196. [Google Scholar] [CrossRef] [PubMed]
[18] Teo, K., Abeysekera, K.W.M., Adams, L., Aigner, E., Anstee, Q.M., Banales, J.M., et al. (2021) Rs641738C > T near MBOAT7 Is Associated with Liver Fat, ALT and Fibrosis in NAFLD: A Meta-Analysis. Journal of Hepatology, 74, 20-30. [Google Scholar] [CrossRef] [PubMed]
[19] Altalbawy, F.M.A., Zwamel, A.H., Sanghvi, G., Roopashree, R., Kumari, M., Kashyap, A., et al. (2025) Interactions in Hepatic Tumor Microenvironment: Potential Targets and Modulations for Effective Therapy. Pathology—Research and Practice, 272, Article ID: 156074. [Google Scholar] [CrossRef] [PubMed]
[20] Su, X., Yan, X. and Zhang, H. (2025) The Tumor Microenvironment in Hepatocellular Carcinoma: Mechanistic Insights and Therapeutic Potential of Traditional Chinese Medicine. Molecular Cancer, 24, Article No. 173. [Google Scholar] [CrossRef] [PubMed]
[21] Hu, B., Yang, X., Xu, Y., Sun, Y., Sun, C., Guo, W., et al. (2014) Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research, 20, 6212-6222. [Google Scholar] [CrossRef] [PubMed]
[22] Qi, Q., Zhuang, L., Shen, Y., Geng, Y., Yu, S., Chen, H., et al. (2016) A Novel Systemic Inflammation Response Index (SIRI) for Predicting the Survival of Patients with Pancreatic Cancer after Chemotherapy. Cancer, 122, 2158-2167. [Google Scholar] [CrossRef] [PubMed]
[23] Zhang, S. and Tang, Z. (2024) Prognostic and Clinicopathological Significance of Systemic Inflammation Response Index in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 15, Article 1291840. [Google Scholar] [CrossRef] [PubMed]
[24] Fucà, G., Guarini, V., Antoniotti, C., Morano, F., Moretto, R., Corallo, S., et al. (2020) The Pan-Immune-Inflammation Value Is a New Prognostic Biomarker in Metastatic Colorectal Cancer: Results from a Pooled-Analysis of the Valentino and TRIBE First-Line Trials. British Journal of Cancer, 123, 403-409. [Google Scholar] [CrossRef] [PubMed]
[25] Kuang, T., Qiu, Z., Wang, K., Zhang, L., Dong, K. and Wang, W. (2024) Pan-Immune Inflammation Value as a Prognostic Biomarker for Cancer Patients Treated with Immune Checkpoint Inhibitors. Frontiers in Immunology, 15, Article 1326083. [Google Scholar] [CrossRef] [PubMed]
[26] Xu, C., Wu, F., Du, L., Dong, Y. and Lin, S. (2023) Significant Association between High Neutrophil-Lymphocyte Ratio and Poor Prognosis in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 14, Article 1211399. [Google Scholar] [CrossRef] [PubMed]
[27] Zhou, Q., Jiang, Z., Ye, T., Yu, L., Wang, Q., Lin, P., et al. (2025) Prognostic Value of Platelet-To-Lymphocyte Ratio in Hepatocellular Carcinoma Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. BMC Gastroenterology, 25, Article No. 437. [Google Scholar] [CrossRef] [PubMed]
[28] Yang, J., Qian, J., Wu, Z., Zhang, W., Yin, Z., Shen, W., et al. (2024) Exploring the Factors Affecting the Occurrence of Postoperative MVI and the Prognosis of Hepatocellular Carcinoma Patients Treated with Hepatectomy: A Multicenter Retrospective Study. Cancer Medicine, 13, e6933. [Google Scholar] [CrossRef] [PubMed]
[29] Crișan, D., Procopeț, B., Crăciun, R., Ștefănescu, H., Gheorghe, L., Sporea, I., et al. (2025) The Role of Easy-To-Use Non-Invasive Scores in the Assessment of Hepatocellular Carcinoma Prognosis—Data from the Romanian Hepatocellular Carcinoma Registry. Journal of Gastrointestinal and Liver Diseases, 34, 205-213. [Google Scholar] [CrossRef] [PubMed]
[30] She, S., Shi, J., Zhu, J., Yang, F., Yu, J. and Dai, K. (2024) Impact of Inflammation and the Immune System on Hepatocellular Carcinoma Recurrence after Hepatectomy. Cancer Medicine, 13, e7018. [Google Scholar] [CrossRef] [PubMed]
[31] Shibutani, M., Maeda, K., Nagahara, H., et al. (2015) Prognostic Significance of the Lymphocyte-To-Monocyte Ratio in Patients with Metastatic Colorectal Cancer. World Journal of Gastroenterology, 21, 9966-9973. [Google Scholar] [CrossRef] [PubMed]
[32] Tian, Y., Zhang, Y., Zhu, W., Chen, X., Zhou, H. and Chen, W. (2018) Peripheral Blood Lymphocyte-To-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma. BioMed Research International, 2018, Article ID: 9434637. [Google Scholar] [CrossRef] [PubMed]
[33] Lin, Z. (2015) Lymphocyte-To-Monocyte Ratio Predicts Survival of Patients with Hepatocellular Carcinoma after Curative Resection. World Journal of Gastroenterology, 21, 10898-10906. [Google Scholar] [CrossRef] [PubMed]
[34] He, T., Xu, B., Wang, L., Wang, Z., Shi, H., Zhong, C., et al. (2025) The Prognostic Value of Systemic Immune-Inflammation Index in Patients with Unresectable Hepatocellular Carcinoma Treated with Immune-Based Therapy. Biomarker Research, 13, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
[35] Li, S., Xu, H., Wang, W., Gao, H., Li, H., Zhang, S., et al. (2019) The Systemic Inflammation Response Index Predicts Survival and Recurrence in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Cancer Management and Research, 11, 3327-3337. [Google Scholar] [CrossRef] [PubMed]
[36] Mao, S., Yu, X., Sun, J., Yang, Y., Shan, Y., Sun, J., et al. (2022) Development of Nomogram Models of Inflammatory Markers Based on Clinical Database to Predict Prognosis for Hepatocellular Carcinoma after Surgical Resection. BMC Cancer, 22, Article No. 249. [Google Scholar] [CrossRef] [PubMed]
[37] Meng, W., Bai, B., Bai, Z., et al. (2016) The Immunosuppression Role of α-Fetoprotein in Human Hepatocellular Carcinoma. Discovery Medicine, 21, 489-494.
[38] Di Carlo, I., Mannino, M., Toro, A., Ardiri, A., Galia, A., Cappello, G., et al. (2012) Persistent Increase in Alpha-Fetoprotein Level in a Patient without Underlying Liver Disease Who Underwent Curative Resection of Hepatocellular Carcinoma. a Case Report and Review of the Literature. World Journal of Surgical Oncology, 10, Article No. 79. [Google Scholar] [CrossRef] [PubMed]
[39] Blank, S., Wang, Q., Fiel, M.I., Luan, W., Kim, K.W., Kadri, H., et al. (2013) Assessing Prognostic Significance of Preoperative Alpha-Fetoprotein in Hepatitis B-Associated Hepatocellular Carcinoma: Normal Is Not the New Normal. Annals of Surgical Oncology, 21, 986-994. [Google Scholar] [CrossRef] [PubMed]
[40] Yao, L., Fan, Z., Wang, M., Diao, Y., Chen, T., Zeng, Y., et al. (2023) Prognostic Value of Serum α‐Fetoprotein Level as an Important Characteristic of Tumor Biology for Patients Undergoing Liver Resection of Early-Stage Hepatocellular Carcinoma (BCLC Stage 0/A): A Large Multicenter Analysis. Annals of Surgical Oncology, 31, 1219-1231. [Google Scholar] [CrossRef] [PubMed]
[41] Liang, L., Wang, M., Zhang, Y., Zhang, W., Zhang, C., Lau, W.Y., et al. (2021) Association of Postoperative Biomarker Response with Recurrence and Survival in Patients with Hepatocellular Carcinoma and High α-Fetoprotein Expressions (>400 ng/ml). Journal of Hepatocellular Carcinoma, 8, 103-118. [Google Scholar] [CrossRef] [PubMed]
[42] Sun, L., Cen, W., Tang, W., Deng, L., Wang, F., Ji, X., et al. (2022) α-Fetoprotein Ratio Predicts α-Fetoprotein Positive Hepatocellular Cancer Patient Prognosis after Hepatectomy. Disease Markers, 2022, Article ID: 7640560. [Google Scholar] [CrossRef] [PubMed]
[43] Hwang, S., Moon, D., Kim, K., Ahn, C., Song, G., Jung, D., et al. (2021) Prognostic Accuracy of the ADV Score Following Resection of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Journal of Gastrointestinal Surgery, 25, 1745-1759. [Google Scholar] [CrossRef] [PubMed]
[44] Sun, L., Cen, W., Zeng, X., Zhong, Y., Deng, L., Yang, J., et al. (2024) The Prognostic Value of α-Fetoprotein Ratio in Patients with Resectable α-Fetoprotein-Negative Hepatocellular Carcinoma. The American Surgeon™, 90, 1240-1249. [Google Scholar] [CrossRef] [PubMed]
[45] Widdershoven, J., van Munster, P., De Abreu, R., Bosman, H., van Lith, T., van der Putten-van Meyel, M., et al. (1987) Four Methods Compared for Measuring Des-Carboxy-Prothrombin (PIVKA-II). Clinical Chemistry, 33, 2074-2078. [Google Scholar] [CrossRef] 
[46] Zhang, J., Qin, S.D., Li, Y., Lu, F., Gong, W.F., Zhong, J.H., et al. (2022) Prognostic Significance of Combined Α-Fetoprotein and CA19-9 for Hepatocellular Carcinoma after Hepatectomy. World Journal of Surgical Oncology, 20, Article No. 346. [Google Scholar] [CrossRef] [PubMed]
[47] Lin, K., Chen, Q., Tang, S., Lin, Z., Zhang, J., Zheng, S., et al. (2023) Prognostic Implications of α-Fetoprotein and C-Reactive Protein Elevation in Hepatocellular Carcinoma Following Resection (PACE): A Large Cohort Study of 2770 Patients. BMC Cancer, 23, Article No. 1190. [Google Scholar] [CrossRef] [PubMed]

为你推荐